Synopsis
The playbook exists. One side has it. Now the other side does too.
Every year, dental practice owners walk into acquisition meetings having spent decades building something real — and walk out with a number that reflects what a buyer could negotiate, not what the practice was worth.
The mechanism is not mystery. It is information asymmetry.
Private equity enters every dental acquisition with a QoE team, a payer mix model, and a forensic audit protocol built on one assumption: the seller doesn't have the same data. They're usually right. The practice owner has a CPA who reads the P&L. The buyer has an analyst who reads the Practice Management Software. That gap — between what the financials show and what the clinical data reveals — is where deals get re-traded after the LOI is signed and the seller has surrendered their leverage.
Phantom EBITDA names the mechanism precisely: the revenue that appears defensible on a P&L but evaporates under a Quality of Earnings audit, enabling buyers to compress valuations after exclusivity is signed and the seller cannot walk away.
This book documents:
- How PE buyers extract, benchmark, and weaponize your own PMS data against you
- The specific clinical compliance findings — D2950 overbilling, hygiene code alternation, payer collection anomalies — that destroy EBITDA at the closing table
- Why the five-year PMS look-back reveals what your three-year P&L cannot hide
- The behavioral signals — refund history patterns, undocumented clinical changes, escheatment liability — that sophisticated buyers flag before you know they're looking
- How to build a Defensible Data Room years before a transaction — and why starting early is the only thing that actually changes your multiple
- The Pre-LOI Forensic Sanitization process: running your own hostile audit before a buyer does, and using the findings to build an institutionally auditable asset that commands a premium
If you are 3-5 years from a potential exit, the clock is already running. If you are 12 months out, you are behind. If you are 6 months out, you are in the kill zone.
The only way to survive a buy-side Quality of Earnings audit is to conduct your own, more hostile audit first.
This book shows you exactly how.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Résultats de recherche pour Phantom EBITDA: The Pre-LOI Defense Playbook for 8-Figure...
Image d'archives
Phantom EBITDA
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
PAP. Etat : New. New Book. Shipped from UK. Established seller since 2000. N° de réf. du vendeur L2-9798254438991
Acheter neuf
EUR 17,56
Expédition à EUR 3,86
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image d'archives
Phantom EBITDA (Paperback)
impression à la demandeVendeur : CitiRetail, Stevenage, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Paperback. Etat : new. Paperback. The playbook exists. One side has it. Now the other side does too. Every year, dental practice owners walk into acquisition meetings having spent decades building something real - and walk out with a number that reflects what a buyer could negotiate, not what the practice was worth. The mechanism is not mystery. It is information asymmetry. Private equity enters every dental acquisition with a QoE team, a payer mix model, and a forensic audit protocol built on one assumption: the seller doesn't have the same data. They're usually right. The practice owner has a CPA who reads the P&L. The buyer has an analyst who reads the Practice Management Software. That gap - between what the financials show and what the clinical data reveals - is where deals get re-traded after the LOI is signed and the seller has surrendered their leverage. Phantom EBITDA names the mechanism precisely: the revenue that appears defensible on a P&L but evaporates under a Quality of Earnings audit, enabling buyers to compress valuations after exclusivity is signed and the seller cannot walk away. This book documents: How PE buyers extract, benchmark, and weaponize your own PMS data against youThe specific clinical compliance findings - D2950 overbilling, hygiene code alternation, payer collection anomalies - that destroy EBITDA at the closing tableWhy the five-year PMS look-back reveals what your three-year P&L cannot hideThe behavioral signals - refund history patterns, undocumented clinical changes, escheatment liability - that sophisticated buyers flag before you know they're lookingHow to build a Defensible Data Room years before a transaction - and why starting early is the only thing that actually changes your multipleThe Pre-LOI Forensic Sanitization process: running your own hostile audit before a buyer does, and using the findings to build an institutionally auditable asset that commands a premiumPhantom EBITDA is not a motivational book about mindset or a broker's guide to maximizing curb appeal. It is a forensic manual written by someone who has sat inside the DSO organizations that designed the acquisition playbook - and now operates exclusively on the sell side. If you are 3-5 years from a potential exit, the clock is already running. If you are 12 months out, you are behind. If you are 6 months out, you are in the kill zone. The only way to survive a buy-side Quality of Earnings audit is to conduct your own, more hostile audit first. This book shows you exactly how. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9798254438991
Acheter neuf
EUR 21,13
Expédition à EUR 43,41
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : 1 disponible(s)